.png)
Austin, TX (March 11, 2025) – Prodigy Health is pleased to announce the availability of HYMPAVZI™ (marstacimab-hncq) by Pfizer, an innovative tissue factor pathway inhibitor (TFPI) designed for routine prophylaxis in adults and adolescents (12 years and older) with hemophilia A or B without inhibitors. HYMPAVZI™ joins Prodigy’s broad suite of products for hemophilia patients.
With a commitment to advancing specialty pharmaceutical access through cutting-edge technology and a patient-first approach, Prodigy Health is proud to distribute this innovative therapy that redefines bleeding disorder management. HYMPAVZI™ provides a novel treatment option with once-weekly subcutaneous administration, reducing the need for traditional factor replacement therapies.
“Prodigy Health remains dedicated to ensuring that providers and patients have access to the most advanced and effective therapies available,” said Keith Patek, President at Prodigy Health. “The launch of HYMPAVZI™ represents an important step forward in treating hemophilia A and B, offering a more seamless and efficient approach to managing these conditions.”
The introduction of HYMPAVZI™ reinforces our commitment to delivering transformative therapies that enhance patient care and provider support.
For more information on HYMPAVZI™ availability and ordering through Prodigy Health, please visit call 877-693-4376 or Contact Us Online.
